|
1
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hsing AW, Tsao L and Devesa SS:
International trends and patterns of prostate cancer incidence and
mortality. Int J Cancer. 85:60–67. 2000. View Article : Google Scholar
|
|
3
|
Wolk A, Andersson SO and Bergström R:
Prospective study of sex hormone levels and risk of prostate
cancer. J Natl Cancer Inst. 89:8201997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Visakorpi T, Kallioniemi AH, Syvänen AC,
Hyytinen ER, Karhu R, Tammela T, Isola JJ and Kallioniemi OP:
Genetic changes in primary and recurrent prostate cancer by
comparative genomic hybridization. Cancer Res. 55:342–347.
1995.PubMed/NCBI
|
|
5
|
Lu W, Singh AK, Khan SA, Senapati D, Yu H
and Ray PC: Gold nano-popcorn-based targeted diagnosis, nanotherapy
treatment, and in situ monitoring of photothermal therapy response
of prostate cancer cells using surface-enhanced Raman spectroscopy.
J Am Chem Soc. 132:18103–18114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jung EJ, Liu G, Zhou W and Chen X: Myosin
VI is a mediator of the p53-dependent cell survival pathway. Mol
Cell Biol. 26:2175–2186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vale RD: Switches, latches, and
amplifiers: Common themes of G proteins and molecular motors. J
Cell Biol. 135:291–302. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Homma K, Yoshimura M, Saito J, Ikebe R and
Ikebe M: The core of the motor domain determines the direction of
myosin movement. Nature. 412:831–834. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Buss F, Spudich G and Kendrick-Jones J:
Myosin VI: Cellular functions and motor properties. Annu Rev Cell
Dev Biol. 20:649–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Szczyrba J, Löprich E, Wach S, Jung V,
Unteregger G, Barth S, Grobholz R, Wieland W, Stöhr R, Hartmann A,
et al: The microRNA profile of prostate carcinoma obtained by deep
sequencing. Mol Cancer Res. 8:529–538. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Morille M, Passirani C, Vonarbourg A,
Clavreul A and Benoit JP: Progress in developing cationic vectors
for non-viral systemic gene therapy against cancer. Biomaterials.
29:3477–3496. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dunn TA, Chen S, Faith DA, Hicks JL, Platz
EA, Chen Y, Ewing CM, Sauvageot J, Isaacs WB, De Marzo AM, et al: A
novel role of myosin VI in human prostate cancer. Am J Pathol.
169:1843–1854. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoshida H, Cheng W, Hung J, Montell D,
Geisbrecht E, Rosen D, Liu J and Naora H: Lessons from border cell
migration in the Drosophila ovary: A role for myosin VI in
dissemination of human ovarian cancer. Proc Natl Acad Sci USA.
101:8144–8149. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Puri C, Chibalina MV, Arden SD, Kruppa AJ,
Kendrick-Jones J and Buss F: Overexpression of myosin VI in
prostate cancer cells enhances PSA and VEGF secretion, but has no
effect on endocytosis. Oncogene. 29:188–200. 2010. View Article : Google Scholar :
|
|
15
|
Fernandes BF, Odashiro AN, Saraiva VS,
Logan P, Antecka E and Burnier MN Jr: Immunohistochemical
expression of melan-A and tyrosinase in uveal melanoma. J Carcinog.
6:62007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Singh D, Febbo PG, Ross K, Jackson DG,
Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, et
al: Gene expression correlates of clinical prostate cancer
behavior. Cancer Cell. 1:203–209. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Demichelis F, Setlur SR, Beroukhim R,
Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD,
Sboner A, et al: Distinct genomic aberrations associated with ERG
rearranged prostate cancer. Genes Chromosomes Cancer. 48:366–380.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Santos JI, Teixeira AL, Dias F, Gomes M,
Nogueira A, Assis J and Medeiros R: Restoring TGFβ1 pathway-related
microRNAs: Possible impact in metastatic prostate cancer
development. Tumour Biol. 35:6245–6253. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang H, Wang B, Zhu W and Yang Z:
Lentivirus-mediated knockdown of myosin VI inhibits cell
proliferation of breast cancer cell. Cancer Biother Radiopharm.
30:330–335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mebratu Y and Tesfaigzi Y: How ERK1/2
activation controls cell proliferation and cell death: Is
subcellular localization the answer? Cell Cycle. 8:1168–1175. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shin SY, Rath O, Choo SM, Fee F, McFerran
B, Kolch W and Cho KH: Positive- and negative-feedback regulations
coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal
transduction pathway. J Cell Sci. 122:425–435. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S,
Malaponte G, et al Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade
inhibitors: How mutations can result in therapy resistance and how
to overcome resistance. Oncotarget. 3:1068–1111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Armin Z, Czernilofsky AP, Gy?Rgy K, Julja
S, Heinz S and Jakob T: Signaling through RAS-RAF-MEK-ERK: From
basics to bedside. Curr Med Chem. 14:601–623. 2007. View Article : Google Scholar
|
|
24
|
Huang B and Porter G: Expression of
proline-rich Akt-substrate PRAS40 in cell survival pathway and
carcinogenesis. Acta Pharmacol Sin. 26:1253–1258. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Madhunapantula SV, Sharma A and Robertson
GP: PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res.
67:3626–3636. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sharma A, Sharma AK, Madhunapantula SV,
Desai D, Huh SJ, Mosca P, Amin S and Robertson GP: Targeting Akt3
signaling in malignant melanoma using isoselenocyanates. Clin
Cancer Res. 15:1674–1685. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bressenot A, Marchal S, Bezdetnaya L,
Garrier J, Guillemin F and Plenat F: Assessment of apoptosis by
immunohistochemistry to active caspase-3, active caspase-7, or
cleaved PARP in monolayer cells and spheroid and subcutaneous
xenografts of human carcinoma. J Histochem Cytochem. 57:289–300.
2009. View Article : Google Scholar :
|
|
28
|
Cristiano BE, Chan JC, Hannan KM, Lundie
NA, Marmy-Conus NJ, Campbell IG, Phillips WA, Robbie M, Hannan RD
and Pearson RB: A specific role for AKT3 in the genesis of ovarian
cancer through modulation of G(2)-M phase transition. Cancer Res.
66:11718–11725. 2006. View Article : Google Scholar : PubMed/NCBI
|
